Parkin (protein)

From WikiMD's WELLNESSPEDIA

(Redirected from Parkinson disease 2)

Parkin_v2.png

Parkin is a protein that in humans is encoded by the PARK2 gene. It is a member of the ubiquitin-protein ligase family, which plays a crucial role in the ubiquitin-proteasome system responsible for protein degradation. Parkin is involved in the regulation of various cellular processes, including mitophagy, the selective degradation of mitochondria by autophagy.

Function[edit]

Parkin functions as an E3 ubiquitin ligase, which facilitates the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to specific substrate proteins. This process tags the substrate proteins for degradation by the proteasome. Parkin is particularly important in maintaining mitochondrial quality control. It is recruited to damaged mitochondria, where it ubiquitinates various mitochondrial surface proteins, marking them for degradation and promoting the removal of dysfunctional mitochondria through mitophagy.

Clinical Significance[edit]

Mutations in the PARK2 gene are associated with autosomal recessive juvenile Parkinsonism (AR-JP), a form of Parkinson's disease (PD) that typically manifests at an early age. These mutations can lead to the loss of Parkin's E3 ligase activity, resulting in the accumulation of damaged mitochondria and neuronal cell death. Understanding the role of Parkin in mitochondrial maintenance has significant implications for developing therapeutic strategies for Parkinson's disease and other neurodegenerative disorders.

Structure[edit]

The Parkin protein contains several functional domains, including an ubiquitin-like domain (Ubl), a RING finger domain, and an in-between ring domain (IBR). These domains are essential for its E3 ligase activity and its interactions with other proteins involved in the ubiquitination process.

Research[edit]

Ongoing research is focused on elucidating the detailed mechanisms by which Parkin regulates mitophagy and how its dysfunction contributes to the pathogenesis of Parkinson's disease. Studies are also exploring potential therapeutic approaches to enhance Parkin activity or compensate for its loss in patients with PARK2 mutations.

See Also[edit]

References[edit]


External Links[edit]

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.